Answers are grounded in this paper and cite their sources.
Objectives: To evaluate the correlation between intrahepatic covalently closed circular DNA (cccDNA) and serum HBV pregenomic Ribo nucleic acid (pgRNA) in treatment-naïve chronic hepatitis B (CHB) patients. Methods: A total of 105 treatment-naïve CHB patients from the Department of Infectious Diseases, Military Hospital 103, Vietnam Military Medical University, were enrolled from 2017 to 2020. Real-time RT-PCR methods were used to quantify serum HBV pgRNA and intrahepatic cccDNA. Clinical and histopathological assessments were also performed. The patients were categorized into two groups: HBeAg-positive CHB (n = 59) and HBeAg-negative CHB (n = 46). Statistical analyses were conducted using Medcalc 20.019. Results: In treatment-naïve patients, the average concentration of cccDNA and HBV RNA were 1.61 ± 0.40 log10 copies/cell and 4.88 ± 1.65 log10 copies/mL, respectively. A positive linear correlation was observed between HBV pgRNA and cccDNA, especially in the overall group and the HBeAg-negative subgroup, as well as in patients with HAI score ≥ 9 and Fibrosis score ≥ 3 (r = 0.49, r = 0.56, and r = 0.57; p < 0.01, respectively). Conclusion: The study findings indicate a positive linear correlation between intrahepatic cccDNA and serum HBV pgRNA in CHB patients. HBV pgRNA can serve as a reliable marker in the management of CHB patients.
No takes yet. Share an insight, caveat, or question.
Đỗ et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: